|
|
Post by peppy on Apr 20, 2016 6:50:29 GMT -5
I greatly appreciate this board and give thanks to the many constructive posters and the hard working administrators. Although I have been reading much about MNKD, both before and now after I purchased shares about a month ago, I still have a lot to learn about the company. Regading the above posted: "Don't forget that Epinephrine won't take that long." Does anyone have an approximate time frame for this TS Epinephrine to be on the market and the approximate market value for it in the US and perhaps for foreign countries where it might be applicable? screencast.com/t/oXcn9FrL3 screencast.com/t/c2xjgEILYp screencast.com/t/oRvnK1x6n6Hs
mnkd.proboards.com/thread/4908/mannkind-2-slides
|
|
|
|
Post by mnholdem on Apr 20, 2016 7:13:13 GMT -5
This report is a bit dated...you can order (for a price, of course) more recent reports that put an estimated 2016 market for epinephrine at $2.4-$2.8 billion.
You may also benefit by reading this Bloomberg article from last fall, which details how Mylan's marketing turned a "ho-hum" drug into a $1 billion blockbuster.
Excerpt:
How Mylan pulled that off is a textbook case in savvy branding combined with a massive public awareness campaign on the dangers of child allergies. Along the way, EpiPen’s wholesale price rose roughly 400 percent from about $57 each when Mylan acquired the product. “They have done a tremendous job of taking an asset that nobody thought you could do much with and making it a blockbuster product,” says Jason Gerberry, a Leerink Partners analyst.
But while EpiPen has given countless parents a sense of security that their children can go out in the world safely, the device’s soaring price—up 32 percent in the past year alone—has forced some families to make difficult choices in order to afford the life-saving medicine. The price increases are among the biggest of any top-selling brand drug, according to DRX, a unit of Connecture that tracks drug pricing. After insurance company discounts, a package of two EpiPens costs about $415, DRX says. By comparison, in France, where Meda sells the drug, two EpiPens cost about $85.
Source: www.bloomberg.com/news/articles/2015-09-23/how-marketing-turned-the-epipen-into-a-billion-dollar-business
It's a good piece for understanding the market that MannKind is preparing to enter with a epinephrine(TS).
|
|
|
|
Post by bradleysbest on Apr 20, 2016 8:35:20 GMT -5
MN...Thanks for the excerpt! We can only hope Afrezza sees a massive public awareness campaign.
|
|
|
|
Post by peppy on Apr 20, 2016 11:10:01 GMT -5
replying to the topic, Building a Marketing Organization What has changed? The internet has brought information and information sharing. Afrezza needs to use this even more. When the price change is announced, that may be an opportunity to get information out there. What else has changed... As the FDA Food and Drug Administration only allows trial study results, in the information share world we live in, people have eyeballs and are still allowed to use them. screencast.com/t/BQ2WnilGfm never before has this information been available as it is today.
Look how close we are and the possible: Kowalski explained that JDRF has been talking with Google and Dexcom about developing a sensor that would be very small (the size of a penny), last for two weeks, and would render blood tests unnecessary. “It’s not a cure, but that’s pretty nice.” (Kowalski mentioned that even current CGM technology has been transformative for his family
truly, how difficult can it be to have a battery heat up a section of skin, draw the blood to it, and scan it for a glucose indicator. we have to be there. Like strapping on a fit bit. come on....
|
|
|
|
Post by lakon on Apr 20, 2016 11:41:44 GMT -5
peppy and mnholdem, great posts on Epi. I started a new thread to continue the discussion about Epinephrine. I had been meaning to pull things together. I think most people do not realize how big the Epi market has become. Most reacted ho-hum to the announcement about Epi, but I was very excited. There are some similarities about how Al Mann thought Afrezza would take market share from Exubera, except Pfizer failed. On the other hand, Mylan made the Epi market what it is today, but their success was an acquisition with great marketing, not innovation. MNKD can innovate and take market share, not to mention expand the size of the market. These are ideas that the new marketing organization will undoubtedly have in their future. Let's brainstorm in a new thread... mnkd.proboards.com/thread/5463/eposphere-key-technosphere-epinephrine
|
|
